地拉罗司是什么药物呢？

(ENRIG) should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time each day. Deferasirox tablets are completely dissolved in water, apple juice or orange juice (100-200 ml) by stirring until a uniform suspension is obtained and then consumed. The remaining drug must be added with a small amount of water, apple juice or orange juice and mixed well before being consumed. It is not recommended to dissolve deferasirox in carbonated drinks or milk because it will cause foam and delay the dispersion speed. Today let’s take a closer look at what kind of drug is deferasirox?

Deferasirox (Enrig) indications: used to treat chronic iron overload in patients with β-thalassemia older than 6 years old due to frequent blood transfusions (monthly administration of concentrated red blood cells ≥ 7 mL/kg); for iron overload caused by children under 6 years old and other transfusion-dependent diseases, Enrig’s safety and effectiveness data for Chinese patients are limited, and it is recommended to use it with caution based on the specific situation of the patient.

The recommended starting daily dose of deferasirox is 20 mg/kg.

For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered.

For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

In patients who have responded well to deferoxamine therapy, an initial dose of deferasirox equal to half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days per week, or equivalent, may start at 20 mg/kg if switched to Enriga.) According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS. During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. Twenty-eight patients died, but none were related to deferasirox treatment.

The results of this trial show that deferasirox (Enrige) can reduce serum ferritin and LPI in transfusion-dependent MDS patients, and some patients' hemogram and liver function can be improved to a certain extent.

The above is the introduction of (Enrige) medicine, I hope it can help you!

Recommended related hot articles: /newsDetail/80691.html